European Medicines Agency adopts positive opinion for MSD’s KEYTRUDA®.

EMA adopts positive opinion for MSD’s KEYTRUDA®

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new extended dosing...
Call for female healthcare scientists to apply for NHS England leadership scheme

Call for female healthcare scientists to apply for leadership scheme

Female healthcare scientists are invited to apply for NHS England’s prestigious leadership development scheme, aimed at mid-career healthcare scientists. The aim of the scheme...

GHO Capital acquires Sterling Pharma Solutions

European specialist investor in healthcare, GHO Capital, has acquired a majority stake in Sterling Pharma Solutions, a specialist in complex and difficult to manufacture...
Servier enters collaborative study with Harvard University researchers

AstraZeneca to present immuno-oncology pipeline progress at AACR

AstraZeneca will share pioneering research and development across its oncology portfolio and extensive next-generation pipeline at the American Association for Cancer Research (AACR) Annual...
focus on science and not geography

Molecular patterns key to predicting breast cancer progression

The genetic and molecular make-up of individual breast tumours holds clues to how a woman’s disease could progress, including the likelihood of it coming...
Phase 3 RELAY study of CYRAMZA® met primary endpoint of PFS

Lilly’s CYRAMZA®Phase 3 RELAY trial meets primary endpoint

The Phase 3 RELAY study of Eli Lilly and Company's CYRAMZA® (ramucirumab) has met its primary endpoint of progression-free survival (PFS), demonstrating a statistically...
Vyxeos accepted for treatment of adults with specific types of high-risk acute myeloid leukaemia within NHS Scotland

SMC accepts Vyxeos® for appropriate AML treatment within NHS Scotland

The Scottish Medicines Consortium (SMC) has accepted the use of Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) 44 mg/100 mg powder for concentrate for solution...
International chemistry survey reveals scale of Brexit concern

No Deal Brexit ‘not an option’ for UK science & innovation

A major new survey commissioned by the Royal Society of Chemistry has revealed the full extent of the sector's concerns over a No Deal...
Exscientia enters drug discovery partnership with Celgene

ProPharma Group acquires Southwood Research

ProPharma Group, a portfolio company of Linden Capital Partners, has announced the acquisition of Southwood Research. Based in Buckinghamshire, Southwood Research is a provider of pre-approval...
NICE approves treatment combination for myeloma patients via Cancer Drugs Fund.

NICE nod for ‘game-changing’ multiple myeloma treatment via CDF

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the National Institute for Health and Care Excellence (NICE) has recommended Darzalex® (daratumumab)...

Latest articles

Investigational therapy has potential to become first oral GLP-1 receptor agonist for those living with type 2 diabetes

Novo Nordisk presents oral semaglitude data at ENDO

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data...
Pf Award Winners

Pf Award Winners on the positive patient outcomes that come from working together

The winners of the Joint Working Pf Award 2018, Senior Coloplast Care Nurse Ruth Christer and NHS Partnership Manager, Coloplast, Jonathan Walker, on the...
Brain scan image: Detecting and managing atrial fibrillation

Detecting and managing atrial fibrillation

The ‘Podiatry and Atrial Fibrillation – Save a life, stop a stroke’ webinar was created to improve the detection and management of atrial fibrillation,...

Popular articles

Brain scan image: Detecting and managing atrial fibrillation

Detecting and managing atrial fibrillation

The ‘Podiatry and Atrial Fibrillation – Save a life, stop a stroke’ webinar was created to improve the detection and management of atrial fibrillation,...
Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer

Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab)

Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab) in early or locally advanced HER2-positive breast cancer. Samsung Bioepis has announced the findings of...
The future of genomics

The future of genomics and precision medicine

How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Investigational therapy has potential to become first oral GLP-1 receptor agonist for those living with type 2 diabetes

Novo Nordisk presents oral semaglitude data at ENDO

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data...
Image of graduates: skills shortage in life sciences

Addressing the skills shortage in life sciences

How can collaboration help to fill the skills shortage gap to ensure that the UK can compete in the global future of life sciences? The...